Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614 This issue

Erratum

PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum

Peng Du, Kaifeng Luo, Guoyong Li, Jisheng Zhu, Qi Xiao, Yong Li, Xingjian Zhang

Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Du P, Luo K, Li G, Zhu J, Xiao Q, Li Y, Zhang X. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614. Available from https://www.medsci.org/v19p0486.htm

File import instruction

Corrected-article in Int J Med Sci, Volume 18, 3588